Immune modulatory effects of oncogenic KRAS in cancer

Shaima’a Hamarsheh; Olaf Groß; Tilman Brummer; Robert Zeiser

doi:10.1038/s41467-020-19288-6

Nature Communications (Oct 2020)

Immune modulatory effects of oncogenic KRAS in cancer

Shaima’a Hamarsheh,
Olaf Groß,
Tilman Brummer,
Robert Zeiser

Affiliations

Shaima’a Hamarsheh: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
Olaf Groß: Institute of Neuropathology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg
Tilman Brummer: Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg
Robert Zeiser: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg

DOI: https://doi.org/10.1038/s41467-020-19288-6
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 11

Abstract

Read online

Oncogenic signalling has been historically associated with sustained cancer cell-intrinsic proliferation, however its role in promoting tumour immunoresistance has also become evident. Here, Hamarsheh and colleagues review and discuss the preclinical work on the immune modulatory effects of oncogenic KRAS and the potential clinical application.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal